Albany, NY -- (SBWire) -- 11/07/2018 --ResearchMoz.us has announced the addition of a report, titled "Global Market Study on Immune Checkpoint Inhibitors: Programmed Death Protein 1 (PD-1) Drug Class to Dominate in Terms of Value Through 2026". The report on the immune checkpoint inhibitors market offers in-depth insights into the key evolution dynamics, revenue forecasts of various segments, key trends, opportunities, technological advances, and the prevailing competitive landscape.
The pressing demand for more effective therapies for cancer against the backdrop of rising prevalence of several types of cancer world over is a key factor driving the demand for immune checkpoint inhibitors. The rising acceptance of immune checkpoint inhibitors for cancer treatment is a key factor driving the market. The various types of cancer for the treatment of which they are used are lung cancer, melanoma, squamous cell carcinoma, urothelial carcinoma, and blood cancer. The rising number of FDA approvals of novel immune checkpoint inhibitors in recent years has set the pace for the expansion of the immune checkpoint inhibitors market. The global immune checkpoint inhibitors market is projected to rise at a robust CAGR of 14.6% from 2018 to 2026.
Get a Sample PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1907258
Burgeoning investments in the research and development (R&D) sector for the approval of immune checkpoint inhibitors for cancer applications are imparting large momentum to the growth of the market. However, the growing trend of regulatory price capping has crippled the overall revenue of drug makers. The adverse reactions witnessed from the use of CTLA-4 immune checkpoint inhibitors in a sizeable percent of patient population is also a key factor hampering the growth of overall market.
Of all the key regional markets for immune checkpoint inhibitors, North America is anticipated to hold the leading share in the global immune checkpoint inhibitors by the end of 2018 end. On the other hand, Asia Pacific is projected to rise at a relatively higher CAGR over 2018–2026.
The various drug classes in the immune checkpoint inhibitors market are programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), and Programmed death-ligand 1 (PD-L1). These are the only approved drug classes. Of these, PD-1 leads the pack at present and is expected to hold its sway throughout the forecast period.
Some of the top players operating in the immune checkpoint inhibitors market are Sanofi, Pfizer, Novartis AG, Roche Holdings AG, Bristol-Myers Squibb, and AstraZeneca. A number of these companies have immune checkpoint inhibitor candidates in the drug pipeline and the product launches are expected to take place in the not-so-distant future. Several manufacturers are focusing on entering into strategic collaborations and agreements in a bid to expand their geographic reach and gain a stronghold over the market. Few of the prominent companies have also forged distribution agreements to get a foothold on the market dynamics.
Immune Checkpoint Inhibitors Market to Explore Lucrative Avenues from Relentless Efforts to Develop Innovative Cancer Therapies